Clinical trials: Prostate Cancer Screening, open to volunteers
- Condition Prostate Cancer Screening
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Prostate Cancer, Prostate Cancer Screening Decision
Clinical Utility of ClarityDX Prostate
ClarityDX Prostate builds upon the utility of total and free PSA as well as simple clinical features in a decision support model to determine a patient's risk of having clinically significant prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer Screening Decision, Prostate Cancer Screening
- Trial name
- NCT06678828
- Testing
- ClarityDX Prostate, ClarityDX Prostate, blinded
- Where
- 5 sites in Canada
- Volunteers
- 1,450 people
- Sponsor
- Nanostics
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Prostate Cancer Detection
Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix
The study is a prospective, multi-center, single cohort study involving up to 10 urological clinics in the US. After provision of informed consent, up to 20 mL of whole blood will be collected from each subject.
- Trial name
- PRIME (NCT07543757)
- Testing
- Proclarix
- Where
- 7 sites in United States
- Volunteers
- 500 people
- Sponsor
- Sequenom, Inc.
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Prostate Cancer Screening
Comparing Standard of Care Biopsy System to a Novel Biopsy Needle System by Computational Pathologic Analysis
Prostate biopsy is the definitive examination to establish the diagnosis of prostate cancer, but up to 40% of these biopsies overestimate or underestimate the severity of the disease.
- Trial name
- NCT06830265
- Testing
- Novel needle biopsy catheter (test)
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Uro-1 Medical